ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
June 01 2022 - 7:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., Founder, President and Chief Executive Officer, will
participate in a fireside chat at the Jefferies 2022 Healthcare
Conference on Wednesday, June 8 at 10:00 am ET in New York.
A live webcast of the fireside chat is available
here and can be accessed by visiting the Investors section of ALX
Oncology’s website at www.alxoncology.com and selecting Events
under the News and Events tab. A replay of the webcasts will be
archived for up to 90 days following the fireside chat dates.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 checkpoint pathway and
bridge the innate and adaptive immune system. ALX Oncology’s lead
product candidate, evorpacept, is a next generation CD47 blocking
therapeutic that combines a high-affinity CD47 binding domain with
an inactivated, proprietary Fc domain. Evorpacept has demonstrated
promising clinical responses across a range of hematologic and
solid malignancies in combination with a number of leading
anti-cancer agents. ALX Oncology intends to continue clinical
development of evorpacept for the treatment of multiple solid tumor
indications and hematologic malignancies.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212) 600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2023 to Apr 2024